Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies: Observational and Cross-sectional Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 216
- 试验地点
- 1
- 主要终点
- Treatment strategy for CIPN
研究概览
简要总结
Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma).
CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival.
There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice.
With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
详细描述
This observational and cross-sectional study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
French oncologist will be contacted by email thanks to the regional cancer networks. Answer to the survey will be done online.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Oncologist
排除标准
- •pain physician
结局指标
主要结局
Treatment strategy for CIPN
时间窗: at day 1
Name of the drug used to treat CIPN and therapeutic adjustments, relay to a pain doctor and use of drugs)
次要结局
- Perception of effectiveness of the treatments used(at day 1)
- Estimation by the oncologist of the percentage of patients affected by CIPN(at day 1)
- Proportion of assessments of the CIPN severity performed by the oncologist using a specific questionnaire(at day 1)
- Proportion of CIPN assessments performed by a neurological examination (neurologist)(at day 1)
- Organ or system speciality of oncologists(at day 1)
- Types of neurotoxic anticancer drugs prescribed(at day 1)
- Working place(at day 1)
- Perception of safety of the treatments used to treat CIPN(at day 1)
- Proportion of CIPN assessments performed by the oncologist with a clinical examination(at day 1)
- Age of oncologists(at day 1)
- Treatment strategy for CIPN prevention(at day 1)
- Number of chemotherapy prescriptions(at day 1)
- Sex of oncologists(at day 1)